{"id":"W3018979351","doi":"10.1016/j.annonc.2020.04.010","title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Foundation Medicine; Pharmacyclics; EMD Serono; Ipsen; Eisai; Merck KGaA; Exelixis; GlaxoSmithKline; Memorial Sloan-Kettering Cancer Center; Astellas Pharma; Alexion Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Axitinib; Sunitinib; Avelumab; Javelin; Renal cell carcinoma; Internal medicine; Oncology; Urology; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000360747,0.000391749,0.001055918,0.0001166327,0.0000846788,0.00001175106,0.0003320478,0.0002548769,0.0001878884],"category_scores_gemma":[0.00079139,0.0002657868,0.0001958388,0.0005051065,0.000225735,0.00008150632,0.0001397065,0.0005529226,0.00005904694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001818825,"about_ca_system_score_gemma":0.0006547281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007618727,"about_ca_topic_score_gemma":0.0004509864,"domain_scores_codex":[0.9966778,0.0003737598,0.001137446,0.000698356,0.0005520942,0.0005605054],"domain_scores_gemma":[0.9964331,0.001470521,0.0006554135,0.0006430439,0.0004671046,0.0003307868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9620368,0.002553663,0.003609543,0.00003574623,0.0002894359,0.0007049223,0.002727892,0.0009503072,0.0003896054,0.00001366092,0.008761759,0.01792668],"study_design_scores_gemma":[0.6196542,0.08321969,0.2445215,0.0001529226,0.0003922448,0.000004804097,0.0003758815,0.0002450808,0.01762243,0.00001597026,0.03337848,0.0004168376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794385,0.0002182391,0.000007376762,0.01278831,0.0002081994,0.001884137,0.0004199124,0.00004482981,0.004990451],"genre_scores_gemma":[0.9949669,0.00007177862,0.0005821708,0.001583362,0.0003457235,0.00005378999,0.002257698,0.0000538238,0.00008478018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3423826,"threshold_uncertainty_score":0.9999794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1030485803041408,"score_gpt":0.3299452875303705,"score_spread":0.2268967072262297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}